Know Cancer

forgot password

ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial

Phase 3
18 Years
Not Enrolling
Cervical Intraepithelial Neoplasia

Thank you

Trial Information

ITIC2 Trial - Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial

Background: Alternatives to surgery are needed for the treatment of cervical intraepithelial
neoplasia (CIN). CIN is associated with persistent human papillomavirus (HPV) infection and
is known to be a potential precursor of cervical cancer. The incidence of CIN has been
increasing during the last decades, especially among young women. Patients diagnosed with
(persistent) high-grade CIN (CIN2/3) are treated with conization. Conization can be regarded
as a safe procedure but peri- and postoperative complications (infections, bleeding, preterm
birth) occur. This raises the need for a conservative treatment alternative for patients
with high-grade CIN. Preliminary data: Imiquimod (IMQ), a toll-like receptor 7 agonist, is
an immune modulating substance approved for the therapy of superficial skin lesions (e.g.
basalioma, actinic keratosis) and HPV associated disease (e.g. anogenital condylomata
acuminata and vulvar intraepithelial neoplasia). In a randomized, placebo-controlled phase
II trial, we previously showed that topical IMQ therapy is an efficacious and feasible
treatment for selected patients with CIN 2/3. Methods: In the present open, randomized,
non-inferiority trial 500 women with CIN 2/3 will be included. This non-profit,
patient-oriented clinical research project will be conducted as an Austrian Gynecologic
Oncology Group (AGO-Austria) trial. Participants will be randomized to either 16 weeks
treatment with topical IMQ (new treatment) or to standard therapy i.e. conization (active
control). This study investigates the non-inferiority of the new treatment, compared to
surgical standard treatment. The primary endpoint is the rate of successful treatment,
defined as negative HPV test result six months after treatment start. Six months after start
of therapy the primary study endpoint is assessed using HPV genotyping. In addition clinical
examinations including colposcopy, HPV genotyping, cytology, and if indicated
colposcopy-guided biopsies of the uterine cervix will be performed. In addition, rates of
CIN persistence/recurrence 6, 12, 18, and 24 months after start of the treatment and rates
of negative HPV test results 12 and 24 months after start of the treatment will be evaluated
in both treatment groups.

Rationale: The need for a conservative treatment modality for patients diagnosed with CIN is
obvious, as many young women need surgical treatment. In this randomized controlled, trial
we will investigate the non-inferiority of a topical IMQ treatment compared to surgical
standard treatment in selected patients diagnosed with CIN 2/3.

Inclusion Criteria

Inclusion criteria:

1. Women aged ≥18 years diagnosed with histologically verified CIN 3 and women aged ≥ 30
years diagnosed with CIN 2

2. Satisfactory colposcopy

3. Signed informed consent

4. Negative pregnancy test

5. Appropriate contraception method for fertile women during active study period

6. Adequate compliance

Exclusion criteria:

1. Adenocarcinoma in situ

2. History of previous conization

3. Malignant disease at the time of inclusion

4. Colposcopy suspicious for invasive disease

5. Pregnancy and lactation period

6. Known allergy or intolerance to IMQ

7. Contraindications to conization or IMQ

8. Symptoms of a clinically relevant disease

9. Known HIV infection

10. Evidence of a clinically significant immunodeficiency

11. Current, reported participation in another experimental, interventional protocol

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

HPV clearance

Outcome Description:

non-inferiority of experimental treatment (Imiquimod) to active control (conization)

Outcome Time Frame:

6 months after treatment completion

Safety Issue:


Principal Investigator

Stephan Polterauer, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medical University of Vienna


Austria: Agency for Health and Food Safety

Study ID:




Start Date:

March 2013

Completion Date:

January 2018

Related Keywords:

  • Cervical Intraepithelial Neoplasia
  • Cervical Intraepithelial Neoplasia, Imiquimod, conization
  • Neoplasms
  • Cervical Intraepithelial Neoplasia
  • Carcinoma in Situ